Eflornithine (Iwilfin) for High-Risk Neuroblastoma
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1702f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Neuroblastoma, Eflornithine. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Eflornithine (Iwilfin) for High-Risk Neuroblastoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1702f
Vancouver
Eflornithine (Iwilfin) for High-Risk Neuroblastoma. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1702f
BibTeX
@article{euvimed2024,
title = {Eflornithine (Iwilfin) for High-Risk Neuroblastoma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1702f}
}
EUVIMED